Obesity-Associated Heart Failure as a Theoretical Target for Treatment With Mineralocorticoid Receptor Antagonists-Reference-Cited by-同舟云学术

Obesity-Associated Heart Failure as a Theoretical Target for Treatment With Mineralocorticoid Receptor Antagonists

Published:2018-09-01 Issue:9 Volume:3 Page:883
ISSN:2380-6583
Container-title:JAMA Cardiology
language:en
Short-container-title:JAMA Cardiol

Author:

Packer Milton¹

Affiliation:

1. Baylor Heart and Vascular Institute, Baylor University Medical Center, Dallas, Texas

Publisher

American Medical Association (AMA)

Subject

Cardiology and Cardiovascular Medicine

Reference65 articles.

1. Aldosterone, mineralocorticoid receptor, and heart failure.;Messaoudi;Mol Cell Endocrinol,2012

2. Aldosterone: effects on the kidney and cardiovascular system.;Briet;Nat Rev Nephrol,2010

3. The effect of aldosterone-antagonist therapy on aortic elastic properties in patients with nonischemic dilated cardiomyopathy.;Vizzardi;J Cardiovasc Med (Hagerstown),2015

4. Serum aldosterone is associated with inflammation and aortic stiffness in normotensive overweight and obese young adults.;Cooper;Clin Exp Hypertens,2012

5. Obesity and cardiovascular disease: role of adipose tissue, inflammation, and the renin-angiotensin-aldosterone system.;Lastra;Horm Mol Biol Clin Investig,2013

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Incidence of atrial and ventricular arrhythmias in obese patients with heart failure with reduced ejection fraction treated with sacubitril/valsartan;Diabetes, Obesity and Metabolism;2023-07-07

2. Obesity and heart failure with preserved ejection fraction: new insights and pathophysiological targets;Cardiovascular Research;2022-07-26

3. Mineralocorticoid Receptor Antagonism Prevents the Synergistic Effect of Metabolic Challenge and Chronic Kidney Disease on Renal Fibrosis and Inflammation in Mice;Frontiers in Physiology;2022-04-07

4. Metabolism and Chronic Inflammation: The Links Between Chronic Heart Failure and Comorbidities;Frontiers in Cardiovascular Medicine;2021-05-05

5. Update on the Impact of Comorbidities on the Efficacy and Safety of Heart Failure Medications;Current Heart Failure Reports;2021-04-09